The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 2.10 — grey zone — between safe and distressedWatch
Where the revenue comes from
Fiscal 2025, as Monte Rosa Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Novartis License Agreement$180.0M
- Two Thousand Twenty Four Novartis License Agreement$150.0M
- Collaboration And License Agreement$46.3M
- Two Thousand Twenty Five Novartis License Agreement$1.8M
Leadership changes
From Monte Rosa Therapeutics, Inc.'s own filings, the day they're filed.
- Edmund Dunn · Directors · departureeff. 2026-04-03
- Matthew Bowen · departureeff. 2026-04-03
- Eric A. Hughes · director · appointmenteff. 2024-12-11
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-11
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Monte Rosa Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Monte Rosa Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.